| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4002405 | American Journal of Ophthalmology | 2014 | 10 Pages |
Abstract
Compared with treatment paradigms validated by clinical trials published at the time, in clinical practice, patients with neovascular AMD received fewer bevacizumab or ranibizumab injections and less-frequent monitoring from 2006 to mid-2011. Factors contributing to this lower injection frequency and visual outcomes associated with reduced utilization need to be researched.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Nancy M. Holekamp, Ying Liu, Wei-Shi Yeh, Yifeng Chia, Szilárd Kiss, Arghavan Almony, Jonathan W. Kowalski,